Â鶹AV

As part of its 2^nd Annual Trainee Research Day invites you to hear our keynote speaker:

Dr. Peter Small, MD

Deputy Director, TB, Bill and Melinda Gates Foundation

Ìý

Modernizing DOTS

Ìý

Wednesday June 18, 2014

Thomson House Ballroom, 3650 McTavish

1:00 PM – 2:00 PM

Ìý

ALL ARE WELCOME

Ìý

Dr. Peter Small, Deputy Director, TB, Bill and Melinda Gates Foundation

For nearly a decade,ÌýPeterÌýSmallÌýserved as the Team Leader for Tuberculosis at the Bill and Melinda Gates Foundation. In that capacity he was responsible for developing the foundation's tuberculosis strategy, building the programsÌýcoreÌýpartnerships, overseeing development of new TBÌýdiagnostics, drugs and vaccines, hiring and managing the team and serving as the foundation's voice for tuberculosis. In 2011 he relocated with his family to New Delhi for two years where designed and implemented the foundation's TB program in India which partners with the Indian Government, WorldÌýBank, USAID, other foundations, and private enterprises to integrate a variety of delivery innovations

Dr.ÌýSmallÌýis a global expert in several aspects of TB treatment, epidemiology, biology and control. He has published more than 150 articles and chapters including studies in the New England Journal of Medicine, Lancet, Science, and Nature that helped to shape the public health response to the resurgence of tuberculosis in the 1990's. Much of this involved collaborative efforts with basic scientists, public health officials and clinicians to use of molecular epidemiologic techniques to answer pragmaticÌýquestionsÌýabout the control of tuberculosis. This work included population based field research projects in San Francisco, Latin America, Africa, Asia and Europe. In 2002, he was awarded theÌýPrincessÌýChichibu Global Tuberculosis Award for his contributions to global tuberculosis control. In addition to his work at the Gates Foundation, until December 2007, he was an Affiliate Professor at the Institute of Systems Biology in Seattle where his lab focused on the nature and consequences of genetic variability within the speciesÌýM. tuberculosisÌýas it pertains to fundamental questions about mycobacterial ecology and evolution.

He served as a member of the Institute of Medicine's committee addressing the elimination of tuberculosis in the United States, the Board of Directors of several public private partnerships, the Technical Advisory Group of the Global Fund, the WHO Stop TB Coordinating Board and is a Fellow in the American Association of Microbiology.

Ìý